NASDAQ$COGT
Cogent Biosciences Inc · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Cogent Biosciences reported financial results for Q4 2021, with ongoing clinical trials and sufficient cash to fund operations into 2024.
Cogent Biosciences announced its Q4 and full year 2021 financial results, highlighting the active enrollment in APEX, SUMMIT, and PEAK clinical trials. The company ended the year with $219.7 million in cash and cash equivalents, expected to fund operations into 2024. An R&D Investor Event is planned for April 8, 2022.
- APEX, SUMMIT and PEAK bezuclastinib clinical trials are actively enrolling patients.
- Initial clinical data presentation from APEX is expected in the first half of 2022.
- An R&D Investor Event is planned for April 8, 2022.
- Ended 2021 with $219.7 million in cash, sufficient to fund operations into 2024.
Headline financials
Revenue & EPS history
Cogent Biosciences · Revenue · Quarterly
$0
Forward guidance
Cogent Biosciences anticipates a cash runway into 2024 and expects to present preliminary clinical data from APEX in the first half of 2022. The company is planning an R&D investor event in April 2022 and anticipates the Cogent Research Team will move into its new facility this spring. AACR poster presentations are expected to be available through the AACR conference website on schedule.
Tailwinds
- Cash runway anticipated into 2024
- Preliminary clinical data from APEX expected in the first half of 2022
- R&D investor event planned for April 2022
- Cogent Research Team anticipated to move into new facility this spring
- AACR poster presentations expected to be available through the AACR conference website on schedule.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2021
+0.9%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+4.5%
Avg return
30 days after
65%
20 / 31 earnings
Positive
+17.8%
Q3 2018
Best reaction
-24.0%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +0.8% | -5.3% | -10.6% | |
| Q3 2025 | -4.4% | -9.1% | +140.2% | |
| Q2 2025 | -5.8% | -9.0% | +7.4% | |
| Q1 2025 | +2.7% | +4.4% | +48.4% | |
| Q4 2024 | -6.3% | +0.9% | -11.4% | |
| Q3 2024 | +0.0% | -14.4% | -19.8% | |
| Q1 2024 | +0.4% | -0.1% | +11.1% | |
| Q4 2023 | +0.7% | -2.8% | -12.4% | |
| Q3 2023 | +3.9% | +3.8% | -2.7% | |
| Q2 2023 | +7.3% | +8.8% | +9.4% | |
| Q1 2023 | -1.5% | -2.6% | -2.9% | |
| Q4 2022 | +0.7% | -5.1% | -13.7% | |
| Q3 2022 | -5.7% | -8.5% | -2.6% | |
| Q2 2022 | +9.6% | +12.1% | +32.7% | |
| Q1 2022 | -24.0% | -26.8% | -10.6% | |
| Q4 2021 | +4.5% | +28.4% | +64.6% | |
| Q3 2021 | +13.7% | +12.1% | -9.9% | |
| Q2 2021 | +5.4% | +13.4% | +3.3% | |
| Q1 2021 | +1.7% | +4.9% | +4.0% | |
| Q4 2020 | +5.9% | +5.5% | +9.0% | |
| Q3 2020 | +13.2% | +9.8% | +14.9% | |
| Q2 2020 | -11.4% | -11.0% | -8.3% | |
| Q1 2020 | +0.5% | +17.9% | +37.1% | |
| Q4 2019 | -3.1% | -15.5% | -18.6% | |
| Q3 2019 | -10.2% | -32.6% | -52.1% | |
| Q2 2019 | +4.4% | +9.3% | +9.0% | |
| Q1 2019 | +0.2% | -1.1% | -26.2% | |
| Q4 2018 | +8.1% | +5.4% | -12.3% | |
| Q3 2018 | +17.8% | +18.5% | -25.0% | |
| Q2 2018 | -5.9% | -12.8% | -27.3% | |
| Q1 2018 | +4.0% | +12.4% | +13.6% | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — | |
| Q3 2016 | — | — | — | |
| Q3 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro